VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CLLS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CLLSCellectis S.A.
$1.06$106M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. CLLS
  4. Financial Ratios

Cellectis S.A. (CLLS) Financial Ratios

Latest Ratios: P/E Ratio -1.6x · EV/EBITDA N/A · ROE -65.3%. (2007–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

CLLS Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$106M$485M$163M$176M$96M$345M$1.2B$727M$679M$1.0B$607M
Enterprise Value$163M$542M$111M$124M$82M$260M$1.0B$413M$228M$743M$318M
P/E Ratio →-1.63——————————
P/S Ratio1.886.653.93232.584.9911.3622.5347.8353.3341.3014.25
P/B Ratio1.406.391.242.070.761.463.722.041.513.642.21
P/FCF——8.35————————
P/OCF——7.38————————

P/E links to full P/E history page with 30-year chart

CLLS EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—7.432.68164.174.268.5619.8927.2117.9429.527.47
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF——5.70————————

CLLS Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin86.6%86.6%77.9%-882.6%55.7%93.9%96.2%25.0%78.5%89.6%96.0%
Operating Margin-45.3%-45.3%-143.5%-12887.7%-467.7%-341.0%-82.9%-813.4%-825.5%-367.8%-150.2%
Net Profit Margin-92.7%-92.7%-88.6%-13385.3%-553.6%-376.3%-158.8%-672.1%-618.1%-394.5%-150.1%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-65.3%-65.3%-34.1%-96.0%-58.6%-41.9%-24.4%-25.3%-21.4%-35.5%-22.7%
ROA-19.1%-19.1%-10.2%-33.9%-33.0%-26.8%-17.3%-21.1%-18.9%-29.9%-18.2%
ROIC-23.5%-23.5%-79.6%-100.7%-51.0%-47.6%-29.3%-442.3%———
ROCE-16.7%-16.7%-30.0%-51.6%-33.8%-27.6%-10.3%-28.8%-28.3%-32.9%-22.7%

CLLS Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity1.581.580.701.000.600.430.350.130.000.000.01
Debt / EBITDA———————————
Net Debt / Equity—0.74-0.40-0.61-0.11-0.36-0.44-0.88-1.00-1.04-1.05
Net Debt / EBITDA———————————
Debt / FCF——-2.65————————
Interest Coverage-7.39-7.39-3.93-20.95-25.04-22.20-14.01-38.05-122.11-185.14-10656.70

CLLS Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.621.621.731.502.284.576.066.2510.407.425.56
Quick Ratio1.621.621.731.502.284.576.036.2110.407.425.56
Cash Ratio1.431.431.571.311.553.775.165.769.646.825.18
Asset Turnover—0.220.110.000.070.080.110.030.030.080.13
Inventory Turnover——————1.213.939.9610.4814.33
Days Sales Outstanding—126.68202.5911182.05334.59373.74137.22367.48632.6666.1531.09

CLLS Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield——12.0%————————
Buyback Yield0.0%0.0%0.0%0.0%0.6%0.0%0.0%0.1%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.6%0.0%0.0%0.1%0.0%0.0%0.0%
Shares Outstanding—$100M$91M$57M$46M$42M$43M$42M$41M$36M$36M

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Clinical Milestone Funding Dependency

Speculative Valuation Amidst Clinical Uncertainty

Based on current market data, Cellectis trades at a price-to-sales multiple of 3.90, a figure that appears to reflect investor optimism regarding the AstraZeneca partnership rather than the company's underlying, non-recurring revenue stream or its persistent inability to generate positive earnings per share.

The lack of a meaningful P/E ratio or positive EBITDA highlights that valuation is driven entirely by the perceived probability of future clinical success rather than current fundamental performance. Investors should monitor whether this premium holds as the company continues to burn cash, as any delay in milestone achievement may lead to a significant contraction in valuation multiples relative to peers.

Capital Compounding Remains Structurally Negative

As reported in recent financial statements, Cellectis's ROIC has remained consistently negative, bottoming out at -35.4% in 2023Q4, which underscores the company's ongoing struggle to generate a return on the capital invested into its proprietary TALEN gene-editing platform and associated manufacturing infrastructure.

The persistent decay in returns on invested capital suggests that the company's R&D spending is not yet translating into value-accretive clinical assets. Without a transition to a commercial-stage model, the company will likely continue to destroy shareholder value, as the cost of capital remains high relative to the company's ability to monetize its intellectual property.

Working Capital Inefficiency Hinders Liquidity

According to historical data, the company's asset turnover ratio has languished at 0.02 to 0.03 in recent quarters, indicating that the firm's asset base is currently underutilized and failing to generate sufficient revenue to offset the high fixed costs of its specialized manufacturing facilities.

The extremely high days sales outstanding and days payable outstanding figures suggest significant friction in the company's cash conversion cycle, likely exacerbated by the lumpy nature of milestone-based partnership payments. This inefficiency warrants further investigation, as it complicates the company's ability to manage its liquidity during periods of low milestone activity.

Rising Debt Burden Increases Risk

Based on the latest quarterly filings, the company's debt-to-equity ratio has climbed to 1.81 as of 2026Q1, signaling an increasing reliance on debt financing to bridge the gap between high R&D burn and the company's lumpy, milestone-dependent revenue inflows.

The negative interest coverage ratio of -11.95 indicates that the company is currently unable to service its debt obligations through operating income alone. This trend suggests that the company's balance sheet is becoming increasingly vulnerable, and investors should monitor the potential for further equity dilution as a necessary step to manage this rising leverage.

Misapplication of Revenue Multiples

The most commonly misapplied metric for Cellectis is the price-to-sales ratio, which obscures the fact that the company's revenue is derived from non-recurring milestone payments rather than sustainable, volume-driven commercial sales, thereby providing a misleading impression of the company's underlying financial health.

Analysts should instead focus on the cash burn rate and the remaining cash runway, as these metrics provide a more accurate assessment of the company's survival risk. Relying on revenue multiples in a pre-commercial biotech context may lead to an overestimation of the company's stability, as it ignores the high probability of future capital raises.

Download Financial Ratios Data

Includes 30+ ratios · 19 years · Updated daily

Consensus & Technical Research Suite
Open CLLS Terminal

CLLS Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

CLLS — Frequently Asked Questions

Quick answers to the most common questions about buying CLLS stock.

What is Cellectis S.A.'s P/E ratio?

Cellectis S.A.'s current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.

What is Cellectis S.A.'s ROE?

Cellectis S.A.'s return on equity (ROE) is -65.3%. The historical average is -41.3%.

Is CLLS stock overvalued?

Based on historical data, Cellectis S.A. is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Cellectis S.A.'s profit margins?

Cellectis S.A. has 86.6% gross margin and -45.3% operating margin.